S&P 500 7,438 +0.40% Nasdaq 25,122 -0.06% Dow Jones 52,208 +0.96% FTSE 100 10,925 +1.76% DAX 25,771 +2.68% Nikkei 225 64,362 -0.88% Hang Seng 25,884 +3.69% WTI Crude 84.64 +2.46% Gold 4,114 +0.96% US 10-Year Treasury Yield 4.663 -0.34% S&P 500 7,438 +0.40% Nasdaq 25,122 -0.06% Dow Jones 52,208 +0.96% FTSE 100 10,925 +1.76% DAX 25,771 +2.68% Nikkei 225 64,362 -0.88% Hang Seng 25,884 +3.69% WTI Crude 84.64 +2.46% Gold 4,114 +0.96% US 10-Year Treasury Yield 4.663 -0.34%

LATEST

Exxon and Chevron profits surge on rising oil prices due to Iran war●Crypto Kiosk Scams Cost Texans $57M as Lawmakers Weigh a Ban●The Tech Download: Anduril CEO Brian Schimpf talks AI in warfare and manufacturing push●Nigeria’s first fully verified direct property marketplace goes live today●BREAKING: NNPC profit jumps 15.8% to N535 billion in June, highest in 10 months●Bitcoin, ether fall, equities rally with broader crypto market on track for best month in a year●Wells Fargo resets Microsoft stock price target●BIS Project Agorá settles $1 million in tokenized cross-border payment trials●Exxon and Chevron profits surge on rising oil prices due to Iran war●Crypto Kiosk Scams Cost Texans $57M as Lawmakers Weigh a Ban●The Tech Download: Anduril CEO Brian Schimpf talks AI in warfare and manufacturing push●Nigeria’s first fully verified direct property marketplace goes live today●BREAKING: NNPC profit jumps 15.8% to N535 billion in June, highest in 10 months●Bitcoin, ether fall, equities rally with broader crypto market on track for best month in a year●Wells Fargo resets Microsoft stock price target●BIS Project Agorá settles $1 million in tokenized cross-border payment trials●

Asia

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%

Markets-Economic Times · 2h ago · 🇮🇳 India

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%

Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and its innovative medicines business despite weak US formulations sales. EBITDA rose 3% to Rs 4,418 crore. The company highlighted semaglutide approvals and said the Organon acquisition remains on track for early 2027.

Read the full story at Markets-Economic Times →

More Asia

OpenAI blinks in face-off with Chinese rivals, drops pricing for some models up to 80%

Business - South China Morning Post · 29m ago

30% of owners looking to sell Hong Kong luxury homes willing to lower prices: agents

Business - South China Morning Post · 29m ago

Bitcoin trades near $64K; key support seen at $63,800-$64,000 amid Fed uncertainty

Markets-Economic Times · 50m ago

Saudi PIF's $55 billion EA deal gets EU approval under subsidy rules

Latest News · 51m ago